by mfenimore | Nov 28, 2023 | Uncategorized
As a result of the COVID-19 pandemic, we have learned valuable lessons pertinent to MS care. This includes knowledge about COVID-19 severity and infection risk (especially as it relates to DMT selection), a much greater understanding of how DMTs affect SARS-CoV-2...
by mfenimore | Nov 28, 2023 | Uncategorized
Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are...
by Stefan Ravello | Nov 28, 2023 | Uncategorized
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments...
by Stefan Ravello | Jul 18, 2023 | Uncategorized
Welcome to our interactive and engaging educational initiative on managing anemia in myelodysplastic syndromes (MDS). Anemia is a common issue in MDS, causing symptoms like fatigue, pallor, shortness of breath, and light-headedness. It can have a significant impact on...
by Stefan Ravello | Jul 18, 2023 | Uncategorized
Alzheimer’s disease (AD) is the leading cause of cognitive impairment and dementia in older individuals (≥ 65 years) throughout the world. In the United States (U.S.), more than 6 million individuals carry this diagnosis, with many yet to be diagnosed. AD follows a...
